Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Treasury Shares: 2013-2025

Historic Treasury Shares for Ani Pharmaceuticals (ANIP) over the last 10 years, with Sep 2025 value amounting to $32.6 million.

  • Ani Pharmaceuticals' Treasury Shares rose 207.91% to $32.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.6 million, marking a year-over-year increase of 207.91%. This contributed to the annual value of $21.0 million for FY2024, which is 108.71% up from last year.
  • Ani Pharmaceuticals' Treasury Shares amounted to $613,972 in Q3 2025, which was up 1.99% from $602,000 recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Treasury Shares high stood at $1.5 million for Q3 2024, and its period low was $80,000 during Q2 2021.
  • In the last 3 years, Ani Pharmaceuticals' Treasury Shares had a median value of $593,000 in 2025 and averaged $701,321.
  • In the last 5 years, Ani Pharmaceuticals' Treasury Shares slumped by 50.00% in 2021 and then spiked by 685.73% in 2023.
  • Quarterly analysis of 5 years shows Ani Pharmaceuticals' Treasury Shares stood at $3.1 million in 2021, then skyrocketed by 62.49% to $5.1 million in 2022, then surged by 97.90% to $10.1 million in 2023, then spiked by 108.71% to $21.0 million in 2024, then spiked by 207.91% to $32.6 million in 2025.
  • Its last three reported values are $32.6 million in Q3 2025, $31.6 million for Q2 2025, and $31.0 million during Q1 2025.